We assess your benefits and explore whether Wegovy or other semaglutide brands are covered, handling the prior authorization process entirely
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
Bitte khl und trocken aufbewahren
Compounding pharmacies can compound medications without clinically significant reasons during shortages, but they may still provide compounded formulations with valid medical justifications, such as excipient-free formulations, specific concentration adjustments, or alternate delivery forms
Pinho RA, Sepa-Kishi DM, Bikopoulos G, Wu MV, Uthayakumar A, Mohasses A, et al